Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/17/2021 | $7.00 → $9.00 | Outperform | SVB Leerink |
| 9/3/2021 | $7.00 | Mkt Perform → Outperform | SVB Leerink |
| 9/3/2021 | Market Perform → Outperform | SVB Leerink | |
| 9/2/2021 | Market Perform → Outperform | SVB Leerink |
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today released its 2025 financial calendar: March 27, 2025: Publication of 2024 financial statements May 13, 2025: Publication of revenue and cash position for 1Q2025 May 22, 2025: Annual General Shareholders Meeting September 17, 2025: Publication of half year financial statements November 13, 2025: Publication of revenue and cash position for 3Q2025 All financial reports are released before market open CET. All corporate information, such as the Company's financial statements and corporate presentations, is available in the Investors section on https://www.innate-pharma.com. Abou
IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL IPH6501 boosts NK cell proliferation and cytotoxicity, showing activity in vitro against a range of B-NHL cell lines, in vivo in various preclinical models and ex vivo in samples from R/R B-NHL patients In vivo studies further validated that IPH6501 augments the ability of peripheral NK cells to migrate and infiltrate tumors Results support clinical development of IPH6501 in R/R B-NHL Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced the publication in Science Immunology of preclinical data demonst
Jonathan Dickinson appointed Chief Executive Officer and Chairman of the Executive Board Encouraging initial FDA feedback received on lacutamab regulatory pathway Lacutamab health-related quality of life and translational data to be presented at the upcoming ASH Annual Meeting IPH4502, a Nectin-4 ADC received FDA clearance of the IND to be developed in solid tumors Preclinical data for proprietary tetra-specific NK cell engager IPH6501 and novel ADC IPH4502 presented at SITC Cash position of €96.4 million1 as of September 30, 2024, anticipated cash runway to end of 2025 Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET Regulatory News: Innate Pharma SA
SVB Leerink reiterated coverage of Innate Pharma with a rating of Outperform and set a new price target of $9.00 from $7.00 previously
SVB Leerink upgraded Innate Pharma from Mkt Perform to Outperform and set a new price target of $7.00
SVB Leerink upgraded Innate Pharma from Market Perform to Outperform
SAR443579/IPH6101, ANKET® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-ALL and HR-MDS SAR443579/IPH6101 continues to show clinical benefit and durable responses along with a favorable safety profile in patients with R/R AML, with 5 complete remissions (4 CR / 1 CRi) achieved at 1 mg/kg, with durable CR (>10 months) observed in 3 patient "We are pleased to see that SAR'579 continues to show promising and durable clinical efficacy along with a favorable safety profile. The ongoing Phase 1/2 study has recently progressed to the Phase 2
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $11.5 price target.
In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety profile consistent with prior studies. Innate will host a virtual KOL event on Tuesday, June 11, 2024 at 4:00PM CEST (10:00AM EDT).
Jonathan Dickinson appointed Chief Executive Officer and Chairman of the Executive Board Encouraging initial FDA feedback received on lacutamab regulatory pathway Lacutamab health-related quality of life and translational data to be presented at the upcoming ASH Annual Meeting IPH4502, a Nectin-4 ADC received FDA clearance of the IND to be developed in solid tumors Preclinical data for proprietary tetra-specific NK cell engager IPH6501 and novel ADC IPH4502 presented at SITC Cash position of €96.4 million1 as of September 30, 2024, anticipated cash runway to end of 2025 Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET Regulatory News: Innate Pharma SA
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that the Company will hold a conference call on Wednesday, November 13, 2024, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2024. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financial Officer Arvind Sood, Executive Vice President, President of US Operations Details for the Virtual Event The live webcast will be availa
Positive results with lacutamab from TELLOMAK Phase 2 study in mycosis fungoides presented at ASCO 2024 NK-Cell engager SAR443579/IPH61011 first-in-human study advanced to Phase 2 and initiation of front-line AML Phase 1/2 combination study Updated data from dose-escalation part presented at EHA 2024 confirm clinical benefit and durable responses in patients with R/R AML IPH45, proprietary anti Nectin-4 ADC progressing towards Phase 1 in H2 2024 Monalizumab data from AstraZeneca-sponsored Phase 2 study in early NSCLC presented at WCLC Cash position of €102.1 million2 as of June 30, 2024, anticipated cash runway to end of 2025 Conference call to be held today at 2:00 p.m. CEST
Jonathan Dickinson joins Innate on November 1 and brings broad experience from leadership roles in biotech and big pharma Current interim CEO and co-founder Hervé Brailly will support the transition Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that its supervisory Board has appointed Jonathan Dickinson as the Company's new Chief Executive Officer (CEO) and Chairman of the Executive Board, effective November 1, 2024. Jonathan Dickinson succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process. Jonathan Dickinson most recently served as Executive Vice President and General Manager, Europe
Two new Executive Board members appointed under recently announced interim CEO, Hervé Brailly Yannis Morel broadens remit to Chief Operating Officer Sonia Quaratino, Chief Medical Officer, appointed to the Executive Board Arvind Sood joins the Company and is appointed Executive Vice President, President of US Operations and to the Executive Board Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that it has strengthened the Company's leadership and corporate governance with the appointment of two new Executive Board members. Arvind Sood, Executive Vice President (EVP), President of US Operations, Dr Sonia Quaratino, EVP, Ch
Appointment of Dr Sally Bennett to the Supervisory Board Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") announced the voting results of its shareholders at the Annual General Meeting ("AGM"), which took place on May 20, 2022, in Marseille. All resolutions were voted on in accordance with the Executive Board's recommendations. A total of 134 votes were cast out of a total of 32,598,725 shares giving right to 33,088,040 voting rights, representing a quorum of 40.88%. The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2022 section of the Compan
6-K - Innate Pharma SA (0001598599) (Filer)
6-K - Innate Pharma SA (0001598599) (Filer)
6-K - Innate Pharma SA (0001598599) (Filer)
SC 13D/A - Innate Pharma SA (0001598599) (Subject)
SC 13D/A - Innate Pharma SA (0001598599) (Subject)
SC 13D - Innate Pharma SA (0001598599) (Subject)